Latest Conference Articles

Expert on IFIS offers practical pearls for success

Expert on IFIS offers practical pearls for success

February 22nd 2021

AAO

Cataract surgeons must consider medication history as part of preoperative evaluation.

The latest updates in cyclophotocoagulation

The latest updates in cyclophotocoagulation

February 13th 2021

GLAUCOMA 360

Shan C. Lin, MD, co-research director, Glaucoma Center of San Francisco, speaks on the highlights from his presentation on the latest in the three forms of cyclophotocoagulation commonly used by clinicians.

Intersection of glaucoma and retina at the pars plana

Intersection of glaucoma and retina at the pars plana

February 11th 2021

GLAUCOMA 360

J. Michael Jumper, MD, a retinal specialist at West Coast Retina (San Francisco, CA), discusses the highlights of his Glaucoma 360 presentation analyzing the impact and lasting effects of intraocular injections and retinal diseases in creating glaucoma as well as the evolving collaboration between retinal and glaucoma specialists.

Managing secondary glaucoma due to intravitreal steroids

Managing secondary glaucoma due to intravitreal steroids

February 9th 2021

GLAUCOMA 360

L. Jay Katz, MD, of the Wills Eye Hospital, Philadelphia, PA, discusses the highlights of his Glaucoma 360 presentation on secondary glaucoma due to intravitreal steroids, and what ophthalmologists can do to minimize the risk of severe visual impairment in patients.

Aerie COO: Expanding innovation of glaucoma therapeutics

Aerie COO: Expanding innovation of glaucoma therapeutics

February 6th 2021

GLAUCOMA 360

Tom Mitro, president, COO of Aerie Pharmaceuticals, discusses the key highlights from an industry panel discussion titled "Innovate without borders," held during the Glaucoma 360 New Horizons Forum, including the company's role in expanding into the global glaucoma therapeutics market.

Tarsus execs discuss origins, treating Demodex blepharitis

Tarsus execs discuss origins, treating Demodex blepharitis

February 4th 2021

AAO

Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.

Glaucoma care after COVID-19: The Pan-American view

Glaucoma care after COVID-19: The Pan-American view

January 31st 2021

GLAUCOMA 360

Results of a survey among ophthalmologists indicate that patients are receiving fewer examinations — with worsening glaucoma, says S. Fabian Lerner, MD, speaking at the Glaucoma 360 New Horizons Forum.

Multi-pressure dial: A new approach to lowering IOP and treating glaucoma

Multi-pressure dial: A new approach to lowering IOP and treating glaucoma

January 31st 2021

GLAUCOMA 360

A new therapy provides noninvasive nighttime IOP control by programming the desired pressure into the device, explained John Berdahl, MD, during the New Horizons Forum.

Glaukos COO shares product updates, 2021 pipeline

Glaukos COO shares product updates, 2021 pipeline

January 31st 2021

GLAUCOMA 360

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.

When is it not glaucoma: Masquerade syndromes

When is it not glaucoma: Masquerade syndromes

January 30th 2021

GLAUCOMA 360

Joseph F. Panarelli, MD, associate professor of ophthalmology, NYU Langone Medical Center, shares some clinical pearls for managing masquerade syndromes and determining when it is not glaucoma.